1
|
Sankhe S, Talla C, Thiam MS, Faye M, Barry MA, Diarra M, Dia M, Ndiaye O, Sembene PM, Diop B, Fall G, Faye O, Faye O, Diagne MM, Loucoubar C. Seroprevalence of Crimean-Congo Hemorrhagic Fever Virus and Rift Valley Fever Virus in human population in Senegal from October to November 2020. IJID Reg 2023; 7:216-221. [PMID: 37153883 PMCID: PMC10160495 DOI: 10.1016/j.ijregi.2023.03.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 03/24/2023] [Accepted: 03/27/2023] [Indexed: 05/10/2023]
Abstract
Objectives Rift Valley Fever and Crimean-Congo Hemorrhagic Fever are two infections classified among the emerging diseases to be monitored with highest priority. Studies undertaken in human and animals have shown endemicity of these two arboviruses in several African countries. However, most of the investigations were carried out on domestic cattle and the studies conducted on human populations are either outdated or limited to a small number of well-known endemic areas. It is then critical to better evaluate the burden of these viruses in Senegal at a national scale. Methods This work relies on a previous seroprevalence survey undertaken in all regions of Senegal at the end of 2020. The existing biobank was used to determine the immunoglobulin G [IgG] Rift Valley Fever and Crimean-Congo Hemorrhagic Fever seroprevalences by indirect enzyme-linked immunosorbent assay. Results The crude seroprevalences of Rift Valley Fever and Crimean-Congo Hemorrhagic Fever were 3.94% and 0.7% respectively, with the northern and central part of the countries as the main exposed areas. However, acute infections reported in both high and low exposed regions suggest sporadic introductions. Conclusions This study gives updated information and could be of interest to support the stakeholders in the management of these zoonoses.
Collapse
Affiliation(s)
- Safietou Sankhe
- Arboviruses and Hemorrhagic Fever Viruses Unit, Virology Department, Institut Pasteur de Dakar, BP220 Dakar, Senegal
- Animal Biology Department, Faculty of Sciences and Techniques, Cheikh Anta Diop University of Dakar, Dakar, Senegal
| | - Cheikh Talla
- Epidemiology, Clinical Research and Data Science Department, Institut Pasteur de Dakar, BP220 Dakar, Senegal
| | - Mareme Seye Thiam
- Epidemiology, Clinical Research and Data Science Department, Institut Pasteur de Dakar, BP220 Dakar, Senegal
| | - Martin Faye
- Arboviruses and Hemorrhagic Fever Viruses Unit, Virology Department, Institut Pasteur de Dakar, BP220 Dakar, Senegal
| | - Mamadou Aliou Barry
- Epidemiology, Clinical Research and Data Science Department, Institut Pasteur de Dakar, BP220 Dakar, Senegal
| | - Maryam Diarra
- Epidemiology, Clinical Research and Data Science Department, Institut Pasteur de Dakar, BP220 Dakar, Senegal
| | - Moussa Dia
- Arboviruses and Hemorrhagic Fever Viruses Unit, Virology Department, Institut Pasteur de Dakar, BP220 Dakar, Senegal
| | - Oumar Ndiaye
- Arboviruses and Hemorrhagic Fever Viruses Unit, Virology Department, Institut Pasteur de Dakar, BP220 Dakar, Senegal
| | - Pape Mbacke Sembene
- Animal Biology Department, Faculty of Sciences and Techniques, Cheikh Anta Diop University of Dakar, Dakar, Senegal
| | - Boly Diop
- Epidemiological Surveillance Division, Prevention Department, Ministry of Health, Dakar, Senegal
| | - Gamou Fall
- Arboviruses and Hemorrhagic Fever Viruses Unit, Virology Department, Institut Pasteur de Dakar, BP220 Dakar, Senegal
| | - Oumar Faye
- Arboviruses and Hemorrhagic Fever Viruses Unit, Virology Department, Institut Pasteur de Dakar, BP220 Dakar, Senegal
| | - Ousmane Faye
- Arboviruses and Hemorrhagic Fever Viruses Unit, Virology Department, Institut Pasteur de Dakar, BP220 Dakar, Senegal
| | - Moussa Moise Diagne
- Arboviruses and Hemorrhagic Fever Viruses Unit, Virology Department, Institut Pasteur de Dakar, BP220 Dakar, Senegal
- Corresponding author
| | - Cheikh Loucoubar
- Epidemiology, Clinical Research and Data Science Department, Institut Pasteur de Dakar, BP220 Dakar, Senegal
| |
Collapse
|
2
|
Dia M, Bob NS, Talla C, Dupressoir A, Escadafal C, Thiam MS, Diallo A, Ndiaye O, Heraud JM, Faye O, Sall AA, Faye O, Fall G. Performance assessment and validation of a Plaque Reduction Neutralization Test (PRNT) in support to Yellow fever diagnostic and vaccine clinical trials. J Med Virol 2023; 95:e28700. [PMID: 36951314 DOI: 10.1002/jmv.28700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2022] [Revised: 02/28/2023] [Accepted: 03/13/2023] [Indexed: 03/24/2023]
Abstract
Yellow fever (YF) virus is a mosquito-borne virus belonging to the Flaviviridae family that circulates in tropical and subtropical areas of Africa and South America. Despite the availability of an effective vaccine, YF remains a threat to travelers, residents of endemic areas, and unvaccinated populations. YF vaccination and natural infection both induce the production of neutralizing antibodies. Serological diagnostic methods detecting YF virus-specific antibodies demonstrate high levels of cross-reactivities with other flaviviruses. To date, the plaque reduction neutralization test (PRNT) is the most specific serological test for the differentiation of flavivirus infections and is considered the reference method for detecting YF neutralizing antibodies and assessing the protective immune response following vaccination. In this study, we developed and validated a YF PRNT. We optimized different parameters including cell concentration and virus-serum neutralization time period and then assessed the intra- and inter-assay precisions, dilutability, specificity, and lower limit of quantification using international standard YF serum, sera from vaccinees and human specimens collected through YF surveillance. The YF PRNT has shown good robustness and 100% of intra-assay precision, 95.6% of inter-assay precision, 100% of specificity, 100% of LLOQ, and 95.3% of dilutability. The test is therefore, suitable for use in the YF diagnostic as well as evaluation of the YF vaccine neutralizing antibody response and risk assessment studies. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Moussa Dia
- Virology Department, Institut Pasteur de Dakar, Dakar, 220, Senegal
| | - Ndeye Sakha Bob
- Virology Department, Institut Pasteur de Dakar, Dakar, 220, Senegal
| | - Cheikh Talla
- Epidemiology, Clinical Research and Data Science Department, Dakar, 220, Senegal
| | - Anne Dupressoir
- Molecular Physiology and Pathology of Endogenous and Infectious Retroviruses Unit, CNRS UMR 9196, Gustave Roussy, Villejuif, France
| | | | - Mareme Seye Thiam
- Epidemiology, Clinical Research and Data Science Department, Dakar, 220, Senegal
| | - Amadou Diallo
- Epidemiology, Clinical Research and Data Science Department, Dakar, 220, Senegal
| | - Oumar Ndiaye
- Virology Department, Institut Pasteur de Dakar, Dakar, 220, Senegal
| | | | - Oumar Faye
- Virology Department, Institut Pasteur de Dakar, Dakar, 220, Senegal
| | | | - Ousmane Faye
- Virology Department, Institut Pasteur de Dakar, Dakar, 220, Senegal
| | - Gamou Fall
- Virology Department, Institut Pasteur de Dakar, Dakar, 220, Senegal
| |
Collapse
|
3
|
Talla C, Loucoubar C, Roka JL, Barry MA, Ndiaye S, Diarra M, Thiam MS, Faye O, Dia M, Diop M, Ndiaye O, Tall A, Faye R, Mbow AA, Diouf B, Diallo JP, Keita IM, Ndiaye M, Woudenberg T, White M, Ting J, Diagne CT, Pasi O, Diop B, Sall AA, Vigan-Womas I, Faye O. Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020. IJID Reg 2022; 3:117-125. [PMID: 35720135 PMCID: PMC8897837 DOI: 10.1016/j.ijregi.2022.02.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Revised: 02/16/2022] [Accepted: 02/17/2022] [Indexed: 11/17/2022]
Abstract
Objectives A nationwide cross-sectional epidemiological survey was conducted to capture the true extent of coronavirus disease 2019 (COVID-19) exposure in Senegal. Methods Multi-stage random cluster sampling of households was performed between October and November 2020, at the end of the first wave of COVID-19 transmission. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies were screened using three distinct ELISA assays. Adjusted prevalence rates for the survey design were calculated for each test separately, and thereafter combined. Crude and adjusted prevalence rates based on test performance were estimated to assess the seroprevalence. As some samples were collected in high malaria endemic areas, the relationship between SARS-CoV-2 seroreactivity and antimalarial humoral immunity was also investigated. Results Of the 1463 participants included in this study, 58.8% were female and 41.2% were male; their mean age was 29.2 years (range 0.20-84.8.0 years). The national seroprevalence was estimated at 28.4% (95% confidence interval 26.1-30.8%). There was substantial regional variability. All age groups were impacted, and the prevalence of SARS-CoV-2 was comparable in the symptomatic and asymptomatic groups. An estimated 4 744 392 (95% confidence interval 4 360 164-5 145 327) were potentially infected with SARS-CoV-2 in Senegal, while 16 089 COVID-19 RT-PCR laboratory-confirmed cases were reported by the national surveillance. No correlation was found between SARS-CoV-2 and Plasmodium seroreactivity. Conclusions These results provide a better estimate of SARS-CoV-2 dissemination in the Senegalese population. Preventive and control measures need to be reinforced in the country and especially in the south border regions.
Collapse
Affiliation(s)
- Cheikh Talla
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Cheikh Loucoubar
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Jerlie Loko Roka
- Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
| | - Mamadou A. Barry
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Seynabou Ndiaye
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Maryam Diarra
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Mareme Seye Thiam
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Oumar Faye
- Virology Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Moussa Dia
- Virology Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Mamadou Diop
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Oumar Ndiaye
- Virology Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Adama Tall
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Rokhaya Faye
- Immunophysiopathology and Infectious Diseases Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Adji Astou Mbow
- Immunophysiopathology and Infectious Diseases Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Babacar Diouf
- Immunophysiopathology and Infectious Diseases Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Jean Pierre Diallo
- Prevention Department, Surveillance Division, Ministry of Health and Social Action, Dakar, Senegal
| | - Ibrahima Mamby Keita
- Prevention Department, Surveillance Division, Ministry of Health and Social Action, Dakar, Senegal
| | - Mamadou Ndiaye
- Prevention Department, Surveillance Division, Ministry of Health and Social Action, Dakar, Senegal
| | - Tom Woudenberg
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
| | - Michael White
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
| | - Jim Ting
- Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
| | | | - Omer Pasi
- Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
| | - Boly Diop
- Prevention Department, Surveillance Division, Ministry of Health and Social Action, Dakar, Senegal
| | - Amadou A. Sall
- Virology Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Inès Vigan-Womas
- Immunophysiopathology and Infectious Diseases Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Ousmane Faye
- Virology Department, Institut Pasteur de Dakar, Dakar, Senegal
| |
Collapse
|